Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas

Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas

Source: 
Bloomberg
snippet: 

Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.